There is now an increasing body of evidence to support the practice of allergen-specific sublingualswallow immunotherapy (SLIT) in the treatment of IgE-mediated respiratory allergies. Recent studies on traditional injection therapy have pointed out that this form of treatment is not only capable to decrease actual allergic symptoms, but may also have long-term clinical and preventive effects and may influence atopy natural history. In the year 2000, our group published a retrospective, multicenter study showing the efficacy and safety of SLIT in a survey of 302 patients. We now carried out a second study on the same patients, with the aim of investigating long-term and preventive effects of SLIT. Beside the well-known safety and efficacy of this treatment (80.8 % of patients reported clinical benefits), SLIT proved also to elicit long term clinical effects: over a mean follow-up of 11.6 months after the end of treatment, 80.8 % of patients stilI mantained the previously achieved benefits. During the follow-up period, only 1% of nonasthma patients reported an onset of respiratory symptoms, and only 9.6 % of patients undergoing new skin tests showed new sensitizations. All the clinical benefits were strongly linked to the length of treatment: patients with long-lasting benefits were treated for a mean length of 29.1 months, while patients showing a return to pre-SLIT condition were treated for a mean 13.3 months. SLIT can obtain long-term and preventive effects so far attributed to injection immunotherapy. 73 0394-6320 (2003) 
There is now an increasing body of evidence to support the practice of allergen-specific sublingual-swallow immunotherapy (SLIT) in the treatment of IgE-mediated respiratory allergies.
As a result of several controlled clinical studies published in recent years, the 1998 WHO Position Paper "Allergen Immunotherapy: Therapeutic Vaccines for Allergic Diseases" adopted for the first time an official position concerning local immunotherapy, stating that sublingual immunotherapy "may be a viable alternative to parenteral injection therapy". (4) Following the publication of the WHO document, additional controlled studies concerning efficacy and tolerability of SLIT have been presented in peer-reviewed journals. In the year 2000, our group published an open, retrospective, multicenter study about this treatment, involving 302 patients treated in seven different Allergy Centers (5) . Notwithstanding the obvious limitations inherent in the study design, this investigation largely Key words: sublingual allergen-specific immunotherapy; length of treatment; long-term effects; preventive effects Mailing address: Dr. Enzo Madanini Istituta Villa Marelli-Ospedale Niguarda Ca'Granda Viale Zara 81 -20159 Milan IEtalY'1 d . '@'l' -mau: enza.ma omm rout confirmed the high efficacy and safety of this form of treatment, as already reported in previous controlled studies conducted on smaller-scale surveys. That study focused on treatments carried out in the years 1995 and 1996: at the time of the study, 256 treatments out of 302 (84.8 %) were still ongoing and the average length of treatment was 18 months (min. 3, max. 46). Only 59 patients (19.5 %) had been treated for at least 24 months.
Five years later, we carried out a new survey on the same patients, with two main purposes. First of all,-assuming that all the treatments had by now been concluded, we wanted to collect more data about SLIT safety and efficacy in a large number ofpatients treated for a longer and adequate period of time. The ultimate study objective, however, was to collect information about patient follow-up, particularly about long-term benefits of SLIT and its possible capability to influence atopy's natural history.
In recent years, there has been mounting interest in these new aspects, since "classic" clinical benefits due to allergen-specific immunotherapy (SIT) have now largely been established. Some studies have already highlighted the long-term efficacy of SIT even after its discontinuation (6-9), a clear advantage over the results observed with pharmacological therapy (10) . As for atopy natural history, several studies have already indicated that SIT seems to be able to prevent the frequent progression of rhinitis into asthma (11) (12) (13) and the onset of new sensitizations- (14) .
In light of the above, a recent Consensus Conference on SIT describes four levels of SIT efficacy:
• Early effect, achieved after initiation of SIT • Persisting effect, persisting during SIT • Long-term effect, after discontinuation of SIT • Preventive effect, prevention of new sensitivities and exacerbation of disease (15) .
These effects are usually referred to the conventional injection therapy. In this study, we evaluated for the first time the same effects or SLIT.
MATERIALS AND METHODS
A questionnaire carrying the name of every single patients had been sent to the seven Allergy Centers participating to the first survey, with the following questions: Being a retrospective survey, all the clinical results were expressed only in terms of physician's report, based upon a personal pool of objective and subjective evaluations. 281 questionnaires out of the original 30 I patients (93,04%) have been returned. Patients in this second study are divided in 156 males (55.5 %) and 125 females, mean age 21.0 years (min 2, max 68, SD 13,08). Demographic characteristics of these patients are comparable to the first survey. Table I 
RESULTS

State and final treatment duration
All the treatments were concluded at the time of the present study. The definitive average duration was 26.4 months (min 7, max 72, SD 12.0). Considering the extract composition, the average length was 29.6 months for grasses, 26.0 for housedust mites and 23.8 for parietaria. Clinical results appear to be related to the length of treatment, as shown in Fig. 1 . Patients with good/very good results were treated for an average of 28.9 months (min 10, max 72), while patients with moderate results were treated for an average of 17.2 months (min 8, max 60) and finally patients whose results were defined as "poor" were treated for a mean 8,.5 months (min 7, max 11).
Clinical results at the end of treatment
The importance of a long SLIT duration is even more clear when evaluating SLIT results in terms of "years of treatment". ( Fig. 2 
Follow-up of clinical results
The average length of patients monitoring has been 11.6 months (min 1, max 28). We asked the Investigators to compare the clinical conditions at the most recent follow-up visit with the results attained at the end of treatment.
As shown in Table IV , 80.8 % of patients maintained the positive results achieved at the end of treatment. This evaluation is also related to the length of treatment (Tab. V).
Since different pollen seasons may produce some variability, we choose to evaluate follow-up results in 147 patients treated with house-dust mites SLIT for perennial allergy. The average length offollow-up in these patients was 11months, and we focused our attention on 61 patients with a minimum period of observation of 6 months after the end of SLIT (See Tab. VI). Once more, the length of treatment is of paramount importance to obtain good follow-up results (Tab. VII). 
Allergy tests results and new sensitizations
Onset of asthma in non -asthmatic patients
A total of 200 patients did not report asthma symptoms at the start of treatment. These subj ects have been followed for an average 9.6 months after the end of SLIT, and only 2 patients (I %) showed a new onset of asthma.
Asthmatic patients
At the start of treatment, 81 patients reported asthma symptoms and were followed for an average 16.4 months after the end of therapy . Out of these 81 patients, 50 (61.7 %) reported "absence of asthma" at the end of SLIT and at the more recent follow-up control. A further 9 patients (11.1 %) reported " no asthma" at the follow-up, while asthma symptoms were still present in the other 22 (27 .2 %) patients at the end of treatment, either " mild intermittent" or " m ild persistent", according to the NIH classification (16 ) . In 5 subjects (6.2 %) asthma symptoms were worse at the follow-up control then at the end of SLIT. 
Adverse reactions since the first study
The seven Centers did not report any adverse reaction.
Pati ents satisfaction
Patients op inion about SLIT efficacy has been collected in 277 subjects. The majority of patients (83.7 % ) expressed satisfaction with the results achieved, while the remaining 45 patients (16.3 %) were unsatisfied. Average SLIT duration was much longer in satisfied patients (28 months) as compared with patients with no sati sfaction (average duration 14 months) . 
DISCUSSION
In 1998, the "Allergen Immunotherapy" WHO Position Paper had considered local routes of immunotherapy, officially stating for the first time that SLIT could provide an effective alternative to the traditional injection therapy, although implying some reservations with the expression "May be ..." and still not endorsing the routine use of this treatment (4) . Following the publication of that document, several controlled studies have been performed, as recommended by the document itself and by many Authors. Several editorial reviews have also appeared, and these serve to further document the efficacy and safety of SLIT (3, 17, 18) and even go one step further than the Position Paper, by stating that SLIT can be administered either to adults and children due to the absence of severe side effects (19) .
"Traditional" clinical results of the present survey, even if limited by the study design, are nevertheless fully consistent with the conclusions of several controlled studies: out of 281 patients included in this second survey, 80.8 % benefited from SLIT. Clinical results were positive and comparable in patients treated with grass extracts (83.3 %) and house-dust mites extracts (85.7 %). Results appeared less favoerable in the overall group of patients treated with Parietaria extracts (64,9 % of positive reports). A possible explanation could be that these patients have been treated for a shorter mean length of time (23.8 months) compared with grasses (29.6 months) and mites (26.0) treatments. As a matter of fact, 30 patients treated with Parietaria extract for at least 24 months (min 24, max 48) reported an incidence of positive results comparable to the other groups (83.3%). As discussed below, the length oftreatment is strongly correlated with all the observed clinical benefits.
Recent published documents emphasize that SIT can achieve more significant clinical benefits than merely "reducing allergic symptoms", underlining the long-term effects of SIT and its influence on atopy natural history (19) (20) (21) (22) (23) . These effects were studied and attributed in the past to the traditional injection SIT. In this study, we extended these evaluations for the first time to SLIT, in an open, retrospective multicenter study, carried out in a large number of patients (281) in seven different Allergy Centers. After a mean follow-up of 11.6 months, 227 patients (80.8 %) still maintained clinical benefits achieved at the end oftreatment. This observation becomes all the more significant when considering patients with perennial mite allergy only, and particularly 61 subjects with such allergy and a minimum followup period of 6 months. The mean follow-up of these patients was 8.3 months, and 47 subjects (78%) had long-term benefits from SLIT, still maintaining the positive results observed at the end of treatment. Furthermore, after a mean treatment length of 32.5 months and a further follow-up period of 16.4 months, 59 patients with initial asthma out of 81 treated (72.8 %) were respiratory symptom-free. To better appreciate the clinical and financial benefits achieved with SLIT, we must recall the observations made with traditional pharmacological therapy, where symptoms and signs of asthma exacerbate very soon, after the discontinuation of treatment, even after prolonged steroid therapy (10) .
During the combined 4 year treatment period and follow-up observation, only 2 patients out of 200 with no asthma symptoms at the beginning of SLIT reported respiratory problems (1 %). Despite "the lack of a control group, such incidence can be considered very successful compared to the rate of asthma development in rhinitis patients, as usually referred in epidemiological studies covering atopy natural history (19, (24) (25) .
In a study by Des Roches et al. it was demonstrated that SIT treatment in children monosensitized to house-dust mite was capable of preventing the onset of new sensitizations, in comparison with a-non-treated control group (14) . 'In our survey, allergy tests were repeated during the follow-up of 156 out of 281 treated subjects and new sensitizations were detected in only 15 subjects (9.6 %). The magnitude of the skin response to the treated allergen was decreased in 84.5 % of subjects, thus indirectly confirming that clinical benefits are supported by immunological mechanisms.
One of the most relevant observations emerging from this study is the clear relationship between the length of treatment and the clinical results: actually, both early benefits from SLIT, observed at the end of treatment, and long term persistence of such benefits are correlated to the length of treatment. A 3-yr length of treatment is generally considered to be adequate in order to achieve long-lasting clinical benefits (27) , although no specific studies investigating the relationship between length of SIT and clinical results have been conducted. This study clearly shows that this relationship does exist for SLIT: only 6.6 % of patients treated for less than one year reported clinical benefits, versus 94 % of subjects treated for more than two years. (Fig. 2 ) With regard to follow-up results, patients showing long-lasting clinical benefits had been treated for an average of 29.1 months: a progressive reduction of the length of treatment was observed in the other "groups of results", down to 13.3 months of treatment in patients complaining a "return to the pre-SLIT clinical condition". This is the first study in which SLIT is evaluated with different and more current clinical criteria. Notwithstanding the limitations of a retrospective, uncontrolled study, the results in particular point to the long-term and preventive effects of SLIT benefits that have thus far been attributed only to traditional injection SIT. The study also underlines the need to carry out the treatment for an adequate length of time, in light of the clear relationship between treatment duration and clinical benefits.
Taking into account these positive results, along with the well-documented safety of this treatment, SLIT can be considered an effective alternative to injection therapy in IgE-mediated respiratory allergies.
